BioCentury
ARTICLE | Company News

Astellas adds new focus area via $3B takeout of gene therapy company Audentes

December 3, 2019 1:19 AM UTC
Updated on Dec 3, 2019 at 1:45 AM UTC

Astellas announced late Monday that it would add genetic regulation as an R&D focus through the acquisition of Audentes for $60 per share, about $3 billion, in cash.

It is at least the fifth acquisition of a gene therapy company announced this year, the largest being the pending Spark Therapeutics Inc. (NASDAQ:ONCE) acquisition by Roche (SIX:ROG; OTCQX:RHHBY), announced in February, for $4.8 billion. ...